• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma

by | Jan 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction

by | Jan 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

A 30-Minute Infusion of Isatuximab Is Safe, Feasible in Patients with Newly Diagnosed Multiple Myeloma

by | Jan 29, 2025 | Myeloma News

Source: Pharmacy Times articles Isatuximab is a CD38-targeting monoclonal antibody that has demonstrated significant clinical success in improving minimal residual disease rates and progression-free survival. Read More

Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis

by | Jan 28, 2025 | Publications

Ther Adv Hematol. 2025 Jan 27;16:20406207251314289. doi: 10.1177/20406207251314289. eCollection 2025. ABSTRACT BACKGROUND: Anti-CD38 monoclonal antibodies (mAbs) have significantly changed the multiple myeloma treatment landscape. This meta-analysis compared the...

PCMMD: A Novel Dataset of Plasma Cells to Support the Diagnosis of Multiple Myeloma

by | Jan 27, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration
  • (no title)
  • (no title)
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT